CLBIO — Corline Biomedical AB Income Statement
0.000.00%
Last trade - 00:00
- SEK272.93m
- SEK255.46m
- SEK25.03m
- 41
- 11
- 11
- 10
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.06 | 3.7 | 7.06 | 23.6 | 25 |
Cost of Revenue | |||||
Gross Profit | 7.15 | 10.3 | 9.1 | 22.7 | 28.4 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 10.6 | 11 | 14 | 21.2 | 26.8 |
Operating Profit | -9.54 | -7.29 | -6.91 | 2.33 | -1.79 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -9.54 | -7.29 | -6.92 | 2.33 | -1.81 |
Net Income After Taxes | -9.54 | -7.29 | -6.92 | 2.33 | -1.81 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.54 | -7.29 | -6.92 | 2.33 | -1.81 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.54 | -7.29 | -6.92 | 2.33 | -1.81 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.57 | -0.425 | -0.339 | 0.108 | -0.084 |
Dividends per Share |